Status:
COMPLETED
Neuroinflammation in COVID-19 and Depression
Lead Sponsor:
Centre for Addiction and Mental Health
Conditions:
Major Depressive Episode
Covid19
Eligibility:
All Genders
18-80 years
Brief Summary
The purpose of this study is to use state of the art brain imaging technology to investigate neuroinflammation in participants with depression after the respiratory symptoms of coronavirus disease 201...
Detailed Description
Participants will undergo two positron emission tomography (PET) scans: one \[18F\]FEPPA scan (for translocator protein (TSPO)) and one \[11C\]SL25.1188 scan (for monoamine oxidase B (MAO-B)) - as wel...
Eligibility Criteria
Inclusion
- Age 18 to 80
- Diagnosis of COVID-19
- Recovered from mild or moderate COVID-19 symptoms. Mild is defined as no evidence of pneumonia or hypoxia. Moderate is defined as presence of clinical symptoms of pneumonia but not severe enough to require ongoing use of supplementary oxygen.
- Recovered from physical COVID-19 symptoms including cough, shortness of breath, fever, chills, or gastrointestinal upset for at least 4 weeks
- New onset major depressive episode (MDE) within 3 months after COVID-19, as verified by the Research Version of Structured Clinical Interview for DSM 5 (SCID-5-RV)
- High-affinity-binder (HAB) or mixed-affinity-binder (MAB) genotype for rs6971 polymorphism, based on saliva genetic testing
Exclusion
- Lifetime history of an autoimmune disease
- Lifetime history of a neurological disease, excluding migraine
- Lifetime diagnosis of Antisocial or Borderline Personality disorder
- Lifetime history of psychotic symptoms prior to COVID-19
- Lifetime diagnosis of Substance of Alcohol Use Disorder
- Use of street drugs, including marijuana, in the past two months
- Presence of cigarette smoking in the past two months
- Positive urine drug or cotinine screen at any timepoint during the study
- Currently pregnant
- Currently breastfeeding
- Use of aspirin or ibuprofen within the past 2 weeks
- Use of any other anti-inflammatory medication or MAO-B inhibitors within the past 4 weeks
- Use of herbal remedies in the past month
- Presence of metal implant, object or electrical devices that are contraindicated for MRI
- Current disorders of coagulation, blood or ongoing use of anticoagulant medication
- Claustrophobia
- Weight over 400lbs and height over 7ft
- History of undergoing a number of PET scans that will lead participants to exceed the annual (20mSv) / lifetime (8 PET scans) radiation by completing this study
- Current participation in another research study
Key Trial Info
Start Date :
June 14 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 21 2023
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT04854785
Start Date
June 14 2021
End Date
December 21 2023
Last Update
April 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre for Addiction and Mental Health
Toronto, Ontario, Canada, M5T 1R8